Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Floxuridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TK1 | P04183 | 3/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | TK2 | O00142 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Floxuridine SCHEMBL18561102 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL6270910 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL9155703 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL13674187 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL18573179 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL17229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL11564431 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL2050487 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL11563300 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL18597573 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903929-B2 | Method for inhibiting dengue virus infection | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11878004-B2 | Method for inhibiting Zika virus infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2024-01-23 | — | — | US | disclosed |
| US-11850236-B2 | Method for inhibiting Zika virus infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-12-26 | — | — | US | disclosed |
| US-11779570-B2 | Method for inhibiting dengue virus infection | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779570-B2 | Method for inhibiting dengue virus infection | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220362217-A1 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220331293-A1 | METHOD FOR INHIBITING DENGUE VIRUS INFECTION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11471443-B2 | Anti-flavivirus compounds and methods of use | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220323419-A1 | METHOD FOR INHIBITING DENGUE VIRUS INFECTION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220323420-A1 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220323420-A1 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20200289471-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-09-17 | — | — | US | disclosed |
| US-20200289471-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-09-17 | — | — | US | disclosed |
| US-20200197369-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-06-25 | — | — | US | disclosed |
| US-20200197369-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-06-25 | — | — | US | disclosed |
| US-20170151240-A1 | F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2017-06-01 | — | — | US | disclosed |
| US-20170056506-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | UNIV SHANGHAI JIAOTONG (CN) | 2017-03-02 | — | — | US | disclosed |
| US-20150031644-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | UNIV SHANGHAI JIAOTONG (CN) | 2015-01-29 | — | — | US | disclosed |
| US-20080241068-A1 | SYSTEM AND METHODS FOR IDENTIFYING INDIVIDUALS AT RISK FOR SYSTEMIC FLUOROPYRIMIDINE TOXICITY | COHEN JAMES M | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903929-B2 | Method for inhibiting dengue virus infection | ZC3HAV1, MAVS, IRF3 | LMNA 1236/4885SMN1; SMN2 1457/4885TK1 2271/4885 |
| US-20220323420-A1 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | ZC3HAV1, MAVS, IRF3 | LMNA 1056/4885SMN1; SMN2 782/4885TK1 2502/4885 |
| US-20200289471-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | MAVS, ZC3HAV1, EIF2AK2 | LMNA 674/4885SMN1; SMN2 458/4885TK1 2889/4885 |
| US-20220362217-A1 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | ZC3HAV1, MAVS, IRF3 | LMNA 1056/4885SMN1; SMN2 782/4885TK1 2502/4885 |
| US-20170056506-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | ABCB4, ABCB1, LCAT | LMNA 1147/4885SMN1; SMN2 3745/4885TK1 620/4885 |
| US-20220323419-A1 | METHOD FOR INHIBITING DENGUE VIRUS INFECTION | ZC3HAV1, MAVS, IRF3 | LMNA 1236/4885SMN1; SMN2 1457/4885TK1 2271/4885 |
| US-11878004-B2 | Method for inhibiting Zika virus infection | ZC3HAV1, MAVS, IRF3 | LMNA 1056/4885SMN1; SMN2 782/4885TK1 2502/4885 |
| US-11471443-B2 | Anti-flavivirus compounds and methods of use | MAVS, ZC3HAV1, EIF2AK2 | LMNA 674/4885SMN1; SMN2 458/4885TK1 2889/4885 |
| US-11850236-B2 | Method for inhibiting Zika virus infection | ZC3HAV1, MAVS, IRF3 | LMNA 1056/4885SMN1; SMN2 782/4885TK1 2502/4885 |
| US-20220331293-A1 | METHOD FOR INHIBITING DENGUE VIRUS INFECTION | ZC3HAV1, MAVS, IRF3 | LMNA 1236/4885SMN1; SMN2 1457/4885TK1 2271/4885 |
| US-11779570-B2 | Method for inhibiting dengue virus infection | ZC3HAV1, MAVS, IRF3 | LMNA 1236/4885SMN1; SMN2 1457/4885TK1 2271/4885 |
| US-20200197369-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | MAVS, ZC3HAV1, EIF2AK2 | LMNA 674/4885SMN1; SMN2 458/4885TK1 2889/4885 |
| US-20150031644-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | ABCB4, ABCB1, LCAT | LMNA 1147/4885SMN1; SMN2 3745/4885TK1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.